FIELD : medicine.SUBSTANCE : invention relates to medicine, specifically to ophthalmology. Surgical treatment of rhegmatogenous retinal detachment involves subtotal vitrectomy, introduction of vitreous solution into body cavity in direction of macular area and 1–2?ml of perfluororganic compound (PFOC), removal of residues of dye and colored ILM. Dye used is MembraneBlue-Dual. After reaching the imaging of the internal limiting membrane, it is removed by fragments using intravitreal tweezers in a circular motion at a tangent to the retinal surface from the area of the lower temporal arcade towards the macular area with area of 3–3.5 of the diameter of the optic disc, PFOC is introduced to lower border of available retinal rupture localized on middle periphery. That is followed by draining the subretinal fluid, and then replacing PFOC with air. That is followed by endolaser coagulation of retina in 2–4?rows in staggered order at 0.15–0.18?mWt along the edges of all available peripheral retinal ruptures. Operation is completed by plugging the vitreal cavity with silicone oil.EFFECT : method provides reducing traumatism of the surgical intervention, improving or preserving visual functions, reducing a risk of forming an epiretinal membrane (ERM) and a cystic macular edema in the postoperative period.1 cl, 2 ex